Evolus to Participate in the Barclays Global Healthcare Conference

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will participate in the Barclays Global Healthcare Conference on March 15, 2022, from 1:35-2:00 p.m. ET. The event emphasizes Evolus’ commitment to delivering innovative products, including their FDA-approved neurotoxin, Jeuveau®, which focuses on aesthetic applications. The presentation will be accessible via an audio webcast on Evolus’ investor relations website, with a replay available for 90 days post-event.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Barclays Global Healthcare Conference.

Event:				Barclays Global Healthcare Conference
Date:				Tuesday, March 15, 2022
Time:				1:35-2:00 p.m. ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau^® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau^® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® is a registered trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005032/en/

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: david.erickson@evolus.com

Source: Evolus, Inc.

FAQ

What event will Evolus, Inc. participate in on March 15, 2022?

Evolus, Inc. will participate in the Barclays Global Healthcare Conference.

What time is Evolus' presentation at the Barclays Global Healthcare Conference?

Evolus' presentation is scheduled for 1:35-2:00 p.m. ET.

How can I access the audio webcast of Evolus' presentation?

The audio webcast can be accessed on Evolus’ investor relations section of their website at www.evolus.com.

What product is Evolus known for in the aesthetic market?

Evolus is known for Jeuveau®, the first neurotoxin dedicated exclusively to aesthetics.

How long will the replay of the webcast be available after the presentation?

The replay of the webcast will be available for 90 days after the presentation.